Chlorambucil versus observation after anti‐Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial
Authors:
Open Access
- 16 January 2009
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 144 (3) , 367-375
Abstract
Summary: Gastric mucosa‐associated lymphoid tissue (MALT) lymphomas are uncommon tumours characterised by a tendency to remain localised for long periods. The aetiological association between MALT lymphomas and Helicobacter pylori is well established. The role of additional chemotherapy after H. pylori eradication in localised MALT lymphomas is unclear. The LY03 trial was designed to establish whether chlorambucil after treatment for H. pylori would help prevent recurrence. Patients were treated with antibiotics for H. pylori infection. Those with successful eradication of H. pylori and no evidence of progression of lymphoma were eligible for randomisation to chlorambucil or observation. Two hundred and thirty‐one patients were registered. Ninety‐seven percent patients had H. pylori eradicated after antibiotics and 59% achieved macroscopically normal gastric mucosa. One hundred and ten patients were randomised. With a median follow‐up of 58 months, six patients were dead and 17 had recurrent/progressive disease. The recurrence/progression rates at 5 years were 11% for chlorambucil, and 21% for observation with a difference of 10%, 95% confidence interval (CI) = −9% to 29%, P = 0·15. No difference was detected in recurrence/progression‐free survival [Hazard Ratio (HR) = 0·96, 95% CI = 0·41–2·2, P = 0·91] or overall survival (HR = 1·93, 95% CI = 0·39–9·58, P = 0·42). This is the first randomised trial to show there is no good evidence to support that additional single agent chemotherapy to anti‐H. pylori treatment contributes to prevent recurrence in localised gastric MALT lymphomas.Keywords
This publication has 24 references indexed in Scilit:
- Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series: Figure 1Gut, 2007
- Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?British Journal of Haematology, 2006
- Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori EradicationJournal of Clinical Oncology, 2005
- Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96)Journal of Clinical Oncology, 2005
- Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral ChemotherapyJournal of Clinical Oncology, 2005
- Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori TherapyJournal of Clinical Oncology, 2005
- The Diminishing Role of Surgery in the Treatment of Gastric LymphomaAnnals of Surgery, 2004
- Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatmentGut, 2001
- Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infectionThe Lancet, 1995
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993